AstraZeneca is considering moving its stock market listing from London, where it is the exchange's most valuable company, to ...

AstraZeneca PLC (NASDAQ:AZN) saw its American Depositary Receipts (ADRs) increase by 2.2% following a report from The Times suggesting that CEO Sir Pascal Soriot has privately shown interest in ...

Sky's James Sillars writes that a government, struggling for authority and prioritising economic growth, can not afford to allow the FTSE 100's biggest company to leave London in favour of New York.

Europe’s drug regulator says there is no evidence AstraZeneca's COVID-19 shot is associated with an increased risk of blood clots.

AstraZeneca’s new clinical trial results are positive but confusing, ... Andrew Testa for The New York Times. By Carl Zimmer and Rebecca Robbins. Published Nov. 24, 2020 Updated Dec. 30, 2020.

AstraZeneca’s vaccine is on track to supply 44 percent of all doses to lower- and middle-income countries, ... Benjamin Mueller is a United Kingdom correspondent for The New York Times.

AstraZeneca has revealed that its COVID-19 vaccine can lead to a condition that causes deadly blood clots.. The condition, known as thrombosis with thrombocytopenia syndrome, is characterized by ...

AstraZeneca and Oxford’s announcement Monday that their vaccine was 79% effective in a 32,000-person trial in the United States buoyed the company’s stock price and impressed government officials.

AstraZeneca is withdrawing its COVID-19 vaccine from worldwide circulation and marketing authorizations. ... By Victor Morton-The Washington Times -Tuesday, May 7, 2024 ...

(Reuters) -AstraZeneca CEO Pascal Soriot is considering moving the company's stock market listing to the U.S., the Times reported on Tuesday, citing multiple sources. Soriot has privately expressed a ...

AstraZeneca, which has a market value of about 156 billion pounds ($213 billion), declined to comment. The company has for years criticised the UK business investment climate.